Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H21N5O3S |
| Molecular Weight | 447.51 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)N=C(CNC(=O)C2=C(C=NC(=C2)C3=CC(C)=CN=C3)C4=NC=CS4)C=C1
InChI
InChIKey=VSOUDUXMPUHJEU-UHFFFAOYSA-N
InChI=1S/C23H21N5O3S/c1-14-8-15(11-24-10-14)19-9-17(18(13-26-19)23-25-6-7-32-23)21(29)27-12-16-4-5-20(30-2)22(28-16)31-3/h4-11,13H,12H2,1-3H3,(H,27,29)
Approval Year
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25248679/ |
MK-3697 plasma | Homo sapiens population: age: ADULT sex: food status: |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MK-3697
Created by
admin on Wed Apr 02 11:27:55 GMT 2025 , Edited by admin on Wed Apr 02 11:27:55 GMT 2025
|
PRIMARY | MedKoo CAT NO: 510214, CAS NO: 1224846-01-8Description: MK-3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists . MK-3697 is also the third insomnia drug, currently being developed by Merck. MK-3697 has Ki = 0.95 nM. Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. In vivo tests results on MK-3697 demonstrated improved stability and TDI profiles as well as excellent sleep efficacy across species. (Last updated: 8/6/2015). | ||
|
46190695
Created by
admin on Wed Apr 02 11:27:55 GMT 2025 , Edited by admin on Wed Apr 02 11:27:55 GMT 2025
|
PRIMARY | |||
|
M8238285OA
Created by
admin on Wed Apr 02 11:27:55 GMT 2025 , Edited by admin on Wed Apr 02 11:27:55 GMT 2025
|
PRIMARY | |||
|
1224846-01-8
Created by
admin on Wed Apr 02 11:27:55 GMT 2025 , Edited by admin on Wed Apr 02 11:27:55 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
